Boston Scientific Corporation vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Boston Scientific Corporation trades at $43.47 (market cap $66.37B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.05. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | XDTE | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $44.76 |
52-Week Low | $42.63 | $36.00 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
XDTE is trading at $38.91, down 0.74% on the day, with a bearish technical signal from moving averages. The ETF focuses on generating high income through a 0DTE covered call strategy on the S&P 500, offering frequent dividend distributions. Recent news highlights its role in providing daily and weekly income, though some sources note risks associated with potential NAV erosion.
The outlook for XDTE centers on its high-yield income strategy, but investors face significant risks from market volatility and NAV decline. While the fund appeals for tax-efficient weekly payouts, its performance is highly sensitive to S&P 500 movements and options market conditions, warranting caution amid bearish technical trends.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →